Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
With
Cystic Fibrosis Foundation
Age
6–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Current participant or willingness to participate in the CFF patient registry database
≥ 6 years of age
Subject has CF as diagnosed by one of the following
* Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test, or
* Two well-characterized genetic mutations in the CFTR gene, or
* Abnormal nasal potential difference (NPD) AND accompanying clinical characteristics consistent with CF. For subjects who lack documentation of either a positive sweat chloride test or an abnormal NPD, and who have only one well-characterized genetic mutation of the CFTR gene, the diagnosis of CF is determined by the Investigator.
FEV1 ≥ 25% predicted and ≤ 90% predicted.
≥ 2 lower respiratory tract cultures positive for PA with results documented in the subject's medical history.
Subject must be able to provide written informed consent/assent prior to any study related procedure; parent/guardian must be able to give written informed consent as necessary prior to any study related procedure.
You may not be if
Subjects who meet the following exclusion criterion are not to be enrolled in this study.
Any serious active medical or psychiatric illness that, in the opinion of the Investigator, would interfere with subject assessment.
Clareo Health | Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients
